C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

EV/OCF
Enterprise Value to OCF

-2.4
Current
0
Median
5.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-2.4
=
Enterprise Value
1.2B HKD
/
Operating Cash Flow
-462.1m CNY
All Countries
Close
Market Cap EV/OCF
CN
Cutia Therapeutics
HKEX:2487
2.1B HKD -2.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -239 043.4
US
Abbvie Inc
NYSE:ABBV
310.3B USD 21.9
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 26.1
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD -112.4
US
Epizyme Inc
F:EPE
94.1B EUR -471
AU
CSL Ltd
ASX:CSL
133.7B AUD 33.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 16.5
US
Seagen Inc
F:SGT
39.3B EUR -73.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -133.4
 
CN
C
Cutia Therapeutics
HKEX:2487
Average EV/OCF: 21.8
Negative Multiple: -2.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -239 043.4
US
Abbvie Inc
NYSE:ABBV
21.9
US
Amgen Inc
NASDAQ:AMGN
26.1
US
Gilead Sciences Inc
NASDAQ:GILD
11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -112.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471
AU
CSL Ltd
ASX:CSL
33.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -73.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -133.4

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Discover More